F-18 fluorodeoxyglucose positron emission computed tomography in the diagnosis of pleural metastases from breast carcinoma

Murat Saricam

doi:10.18203/2349-2902.isj20200819

Authors

Murat Saricam Department of Thoracic Surgery, Namik Kemal University, Tekirdag, Turkey

DOI:

https://doi.org/10.18203/2349-2902.isj20200819

Keywords:

Breast cancer, Diagnosis, Pleural metastases, PET/CT

Abstract

Background: This study aimed to investigate the feasibility of F-18 fluorodeoxyglucose (FDG) positron emission computed tomography (PET/CT) in identifying the pleural invasion of metastatic breast cancers.

Methods: A retrospective study was conducted to include 75 patients with untreated breast cancer who had undergone thoracoscopy to drain pleural effusions and to perform pleural biopsies. Whole group of patients were evaluated in terms of age, type of primary breast cancer, macroscopic appearance of pleura during thoracoscopy, maximum standardized FDG uptake value (SUV) reported by PET/CT scan in addition to presence of malignancy detected in pleura and/or pleural effusion.

Results: All of 75 patients were female and mean age was 56.12±11.70. Metastatic disease was diagnosed in the pleura of 40 (53.3%) and in the pleural effusion of 43 (57.3%) patients. The sensitivity and specificity of PET/CT in detecting pleural metastases of breast carcinoma was calculated as 88.2% and 96.2% whereas PET/CT demonstrated sensitivity of 91.9% and specificity of 91.3% in identifying malignant pleural effusion. Cut-off values of FDG uptake were 4.25 for pleural metastases and 3.85 for malignant pleural effusions. PET/CT also indicated a false negative rate of 12.5%, a false positive rate of 16.28% and an overall accuracy rate of 85.33% in the diagnosis of pleural metastasis of breast carcinoma.

Conclusions: PET/CT reporting an FDG uptake over 4 in the pleura or pleural effusion is beneficial in managing the patients with the suspicion of pleural metastases from breast cancer.

Metrics

Metrics Loading ...

References

Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Inter Med. 2013;274(2):113-26.

Scully OJ, Bay B, Yip G, Yu Y. Breast cancer metastasis. Can Gen Prot. 2012;9:311-20.

Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10(1):2.

Sledge GW. Curing metastatic breast cancer. J Onc Prac. 2016;12(1):11-3.

Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009;69(12):4951-3.

Jyotsana N, Zhang Z, Himmel LE, Yu F, King MR. Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Sci Advan. 2019;5(7):eaaw4197.

Karagiannis GS, Goswami S, Jones JG, Oktay MH, Condeelis JS. Signatures of breast cancer metastasis at a glance. J Cell Sci. 2016;129(9):1751-8.

Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Therapy. 2018;19(10):858-68.

Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Oncogene. 2013;32(20):2527-33.

Xiao W, Zheng S, Liu P, Zou Y, Xie X, Yu P, et al. Risk factors and survival outcomes in patients with breast cancer and lung metastasis: a population‐based study. Cancer Med. 2018;7(3):922-30.

Friedel G, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, et al. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardio-thoracic Surg. 2002;22(3):335-44.

Shoji M, Qian WP, Nagaraju GP, Brat DJ, Pessolano D, Luzietti R, et al. Inhibition of breast cancer metastasis to the lungs with UBS109. Oncotarget. 2018;9(90):36102-9.

Rawindraraj AD, Zhou CY, Pathak V. Delayed breast cancer relapse with pleural metastasis and malignant pleural effusion after long periods of disease‐free survival. Respirol Case Rep. 2018;6(9):e00375.

Schuster DM. Clinical Utility of PET Scanning in Breast Cancer Management. Am J Hematol/Oncol®. 2015;11(6).

Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact?. Am J Roentgenol. 2019;213(2):254-65.

Zhang FC, Xu HY, Liu JJ, Xu YF, Chen B, Yang YJ, et al. 18F‑FDG PET/CT for the early prediction of the response rate and survival of patients with recurrent or metastatic breast cancer. Oncol Letters. 2018;16(4):4151-8.

Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast cancer. J Nucl Med. 2016;57(1):17-26.

Taalab K, Abutaleb AS, Moftah SG, Abdel-Mutaleb MG, Abdl-Mawla YA. The Diagnostic Value of PET/CT in Breast Cancer Recurrence and Metastases. Egyptian J Nucl Med. 2017;15(2).

Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27(1):215-29.

Abo-Sheisha DM, Badawy ME. The diagnostic value of PET/CT in recurrence and distant metastasis in breast cancer patients and impact on disease free survival. EgypJ Radiol Nuclear Med. 2014;45(4):1317-24.

Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Annal oncol. 2012;23(9):2277-82.

Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado Bolton RC, Orcajo Rincon J, Garcia Garzon JR, et al. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. Tumor Biol. 2017;39(10):1010428317728285.

Orevi M, Freedman N, Tahover E, Uziely B, Chisin R, Peretz T, et al. Is 18F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?. Acta Oncol. 2016;55(2):244-7.

Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM. FDG PET/CT in the management of primary pleural tumors and pleural metastases. Am J Roentgenol. 2013;201(2):215-26.

Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koëter GH, et al. PET for the evaluation of pleural thickening observed on CT. J Nuclear Med. 2004;45(6):995-8.

Hong S, Li J, Wang S. 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22(2):139-43.

Radan L, Ben‐Haim S, Bar‐Shalom R, Guralnik L, Israel O. The role of FDG‐PET/CT in suspected recurrence of breast cancer. Cancer: Interdisciplinary Inter J Am Cancer Soci. 2006;107(11):2545-51.

Sun Y, Yu H, Ma J, Lu P. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PloS One. 2016;11(8).

Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Resp Rev. 2016;25(140):189-98.

Arnold DT, Maskell N. Imaging for malignant pleural effusions-still no routine role of positron emission tomography. J Thora Dis. 2019;11(4):1079.

Hallifax RJ, Talwar A, Wrightson JM, Edey A, Gleeson FV. State-of-the-art: Radiological investigation of pleural disease. Resp Med. 2017;124:88-99.